Primary Osteoporosis.

Endocrine development Pub Date : 2015-01-01 Epub Date: 2015-06-12 DOI:10.1159/000381037
Paul Arundel, Nick Bishop
{"title":"Primary Osteoporosis.","authors":"Paul Arundel,&nbsp;Nick Bishop","doi":"10.1159/000381037","DOIUrl":null,"url":null,"abstract":"<p><p>Primary osteoporosis in childhood encompasses a range of bone fragility conditions that typically have a genetic origin. Understanding of the pathophysiology and genetics of primary osteoporosis has increased dramatically over the past 10 years. The clinical manifestations and consequences of the disease range from mild to severe, with the degree of growth retardation and bony deformity reflecting the severity and the underlying pathology. In children, primary osteoporosis is most commonly caused by one of the forms of osteogenesis imperfecta, which comprises a group of disorders characterised by abnormalities in type I collagen synthesis or processing. Diagnosis of any primary osteoporotic condition depends on the clinical history and examination but may be supported by other investigations, including various imaging techniques, histology and genetic analyses. Good management requires a multidisciplinary approach involving paediatricians, surgeons and allied health professionals, amongst others. Bisphosphonate therapy has revolutionised the approach to management and has positively modified outcomes for many children and their families. Physiotherapy and occupational therapy are the keys to optimising independence in mobility and daily living. Surgery is required in many severe cases to straighten limbs or stabilise the spine. Bisphosphonates remain the mainstay of medical treatment, but there are a number of alternative therapeutic agents under investigation that may further improve management of primary osteoporosis in children over the coming years.</p>","PeriodicalId":72906,"journal":{"name":"Endocrine development","volume":"28 ","pages":"162-175"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000381037","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000381037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/6/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Primary osteoporosis in childhood encompasses a range of bone fragility conditions that typically have a genetic origin. Understanding of the pathophysiology and genetics of primary osteoporosis has increased dramatically over the past 10 years. The clinical manifestations and consequences of the disease range from mild to severe, with the degree of growth retardation and bony deformity reflecting the severity and the underlying pathology. In children, primary osteoporosis is most commonly caused by one of the forms of osteogenesis imperfecta, which comprises a group of disorders characterised by abnormalities in type I collagen synthesis or processing. Diagnosis of any primary osteoporotic condition depends on the clinical history and examination but may be supported by other investigations, including various imaging techniques, histology and genetic analyses. Good management requires a multidisciplinary approach involving paediatricians, surgeons and allied health professionals, amongst others. Bisphosphonate therapy has revolutionised the approach to management and has positively modified outcomes for many children and their families. Physiotherapy and occupational therapy are the keys to optimising independence in mobility and daily living. Surgery is required in many severe cases to straighten limbs or stabilise the spine. Bisphosphonates remain the mainstay of medical treatment, but there are a number of alternative therapeutic agents under investigation that may further improve management of primary osteoporosis in children over the coming years.

原发性骨质疏松症。
儿童期原发性骨质疏松症包括一系列典型的有遗传起源的骨脆弱状况。在过去的十年中,对原发性骨质疏松症的病理生理学和遗传学的了解急剧增加。该病的临床表现和后果从轻到重,以生长迟缓和骨骼畸形的程度反映其严重程度和潜在病理。在儿童中,原发性骨质疏松症最常由一种形式的成骨不完全性引起,它包括一组以I型胶原合成或加工异常为特征的疾病。任何原发性骨质疏松症的诊断都取决于临床病史和检查,但也可能得到其他调查的支持,包括各种成像技术、组织学和遗传分析。良好的管理需要多学科方法,包括儿科医生、外科医生和专职卫生专业人员等。双膦酸盐治疗彻底改变了治疗方法,并对许多儿童及其家庭产生了积极的影响。物理治疗和职业治疗是优化行动和日常生活独立性的关键。在许多严重的情况下,需要手术来伸直四肢或稳定脊柱。双膦酸盐仍然是医学治疗的主要药物,但有一些替代治疗药物正在研究中,这些药物可能在未来几年进一步改善儿童原发性骨质疏松症的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信